John V Fenice, MD | |
2601 Annand Dr, Suite 4, Wilmington, DE 19808-3719 | |
(302) 998-3334 | |
(302) 998-8985 |
Full Name | John V Fenice |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 22 Years |
Location | 2601 Annand Dr, Wilmington, Delaware |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1033138169 | NPI | - | NPPES |
222137644 | Other | NJ | BCBSNJ |
900000011100 | Other | NJ | AMERICHOICE |
222137644 | Other | NJ | CHAMPUS/TRICARE |
0091111 | Medicaid | NJ |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | MA79983 (New Jersey) | Secondary |
207Q00000X | Family Medicine | C1-0007714 (Delaware) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Christiana Hospital | Newark, DE | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Coras Wellness And Behavioral Health Llc | 1456741248 | 15 |
Heritage Medical Associates, P.a. | 6204916067 | 3 |
News Archive
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Pericytes, a little-understood type of cell on the brain's blood vessels, grow into the empty space left when neighboring pericytes die, report researchers at the Medical University of South Carolina in a January 2nd, 2018 article in Cell Reports.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Whether they dangle from keychains, spritz from pens or froth and pump out of clinic and classroom dispensers, hand sanitizers are convenient alternatives to handwashing, and they do work.
› Verified 8 days ago
Entity Name | Heritage Medical Associates, P.a. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1609073493 PECOS PAC ID: 6204916067 Enrollment ID: O20080107000107 |
News Archive
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Pericytes, a little-understood type of cell on the brain's blood vessels, grow into the empty space left when neighboring pericytes die, report researchers at the Medical University of South Carolina in a January 2nd, 2018 article in Cell Reports.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Whether they dangle from keychains, spritz from pens or froth and pump out of clinic and classroom dispensers, hand sanitizers are convenient alternatives to handwashing, and they do work.
› Verified 8 days ago
Entity Name | Img Associates Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1134424351 PECOS PAC ID: 2466634563 Enrollment ID: O20170315001893 |
News Archive
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Pericytes, a little-understood type of cell on the brain's blood vessels, grow into the empty space left when neighboring pericytes die, report researchers at the Medical University of South Carolina in a January 2nd, 2018 article in Cell Reports.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Whether they dangle from keychains, spritz from pens or froth and pump out of clinic and classroom dispensers, hand sanitizers are convenient alternatives to handwashing, and they do work.
› Verified 8 days ago
Entity Name | Northeast Treatment Centers Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1083712830 PECOS PAC ID: 5092060756 Enrollment ID: O20200513002512 |
News Archive
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Pericytes, a little-understood type of cell on the brain's blood vessels, grow into the empty space left when neighboring pericytes die, report researchers at the Medical University of South Carolina in a January 2nd, 2018 article in Cell Reports.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Whether they dangle from keychains, spritz from pens or froth and pump out of clinic and classroom dispensers, hand sanitizers are convenient alternatives to handwashing, and they do work.
› Verified 8 days ago
Entity Name | Coras Wellness And Behavioral Health Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023686284 PECOS PAC ID: 1456741248 Enrollment ID: O20211210000182 |
News Archive
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Pericytes, a little-understood type of cell on the brain's blood vessels, grow into the empty space left when neighboring pericytes die, report researchers at the Medical University of South Carolina in a January 2nd, 2018 article in Cell Reports.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Whether they dangle from keychains, spritz from pens or froth and pump out of clinic and classroom dispensers, hand sanitizers are convenient alternatives to handwashing, and they do work.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
John V Fenice, MD 2601 Annand Dr, Suite 4, Wilmington, DE 19808-3719 Ph: (302) 998-3334 | John V Fenice, MD 2601 Annand Dr, Suite 4, Wilmington, DE 19808-3719 Ph: (302) 998-3334 |
News Archive
The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Pericytes, a little-understood type of cell on the brain's blood vessels, grow into the empty space left when neighboring pericytes die, report researchers at the Medical University of South Carolina in a January 2nd, 2018 article in Cell Reports.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
Whether they dangle from keychains, spritz from pens or froth and pump out of clinic and classroom dispensers, hand sanitizers are convenient alternatives to handwashing, and they do work.
› Verified 8 days ago
Jennifer Maxwell, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4550 New Linden Hill Rd, Wilmington, DE 19808 Phone: 302-525-4337 | |
Charlene Browne, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 31/32 A Trolley Square, Wilmington, DE 19806 Phone: 302-777-5473 | |
Dr. Michelle Elaine Papa, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1100 S Broom St, Wilmington, DE 19805 Phone: 302-656-5416 Fax: 302-656-5435 | |
Heather Bittner-fagan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1401 Foulk Rd, Suite 100b, Wilmington, DE 19803 Phone: 302-477-3300 Fax: 302-477-3168 | |
Lakan Karlo G Magat, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2300 Pennsylvania Ave, Suite 1a, Wilmington, DE 19806 Phone: 302-655-0355 Fax: 302-655-4833 | |
Patricia F Bankes, CRNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1072 Justison St, Wilmington, DE 19801 Phone: 302-661-7400 Fax: 302-661-7476 | |
Steven E. Diamond, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 900 Foulk Rd, Suite 200, Wilmington, DE 19803 Phone: 302-655-8868 Fax: 302-655-3744 |